1638N mice, which are heterozygous for a germline mutation in Apc, typically develop three to ®ve spontaneous intestinal tumors per animal. In most cases this is associated with allelic loss of wildtype Apc. We have previously reported that the multiplicity of intestinal tumors is increased dramatically by crossing Apc   1638N with an Mlh1-de®cient mouse strain that represents an animal model of hereditary non-polyposis colorectal cancer (HNPCC). The increased tumor multiplicity in these mice was associated with somatic mutations in the Apc tumor suppressor gene. Here, we have examined the nature and distribution of 91 Apc mutations implicated in the development of intestinal tumors in Mlh1
Introduction
DNA mismatch repair (MMR) is critically important for maintaining genomic ®delity through the recognition and repair of incorrectly paired nucleotides. Such lesions can arise by DNA polymerase incorporation errors, heteroduplex formation during genetic recombination, or by chemical damage to existing nucleotides such as deamination of methyl cytosine (Branch et al., 1995; de Wind et al., 1995; Fishel and Kolodner, 1995; Saparbaev et al., 1996) . Mammalian cells contain multiple homologs of the MutS and MutL proteins that are essential for MMR in E. coli. MSH2, MSH3, and MSH6 are homologs of MutS, while MLH1, PMS2, and PMS1, are homologs of MutL (for review, see Kolodner, 1996) . MSH2 protein is capable of forming complexes with either MSH3 or MSH6 (Marsischky et al., 1996) . Both these complexes are involved in recognizing mismatched DNA and have dierent, but overlapping, mismatch recognition speci®cities (Marsischky et al., 1996; Umar et al., 1998) . Genetic and biochemical studies indicate that the MutL homolog MLH1 forms complexes with PMS1 and PMS2 in yeast and human cells, respectively. These heterodimers are known as MutLa, and in each case both subunits are essential for MMR (Li and Modrich, 1995; Prolla et al., 1994a,b) . Although the speci®c biochemical function of the MutLa complex has not yet been determined, it appears to interact with MSH2-containing mismatch recognition protein complexes and enhances the ability of the latter to bind to mismatched DNA (Habraken et al., 1997 (Habraken et al., , 1998 .
Defects in MMR in humans are directly involved in the etiology of Hereditary Non-Polyposis Colorectal Cancer (NHPCC), an autosomal dominant disorder that confers predisposition to colonic and other tumors. Most patients with HNPCC harbor germline mutations in one of several genes involved in DNA MMR, and tumors from HNPCC patients frequently show DNA microsatellite instability (Marra and Boland, 1995) . Germline mutations in hMLH1 and hMSH2 are the most prominent of the diseasepredisposing mutations and account for approximately 60% of the HNPCC kindreds (Peltomaki and de la Chapelle, 1997) .
Familial Adenomatous Polyposis (FAP), another autosomal dominant syndrome that imparts predisposition to colorectal cancer, is caused by germline mutations in the tumor suppressor gene APC Joslyn et al., 1991; Kinzler et al., 1991) . Loss of certain APC functions is a critical event in early stages of tumor formation and hence the gene has been termed a`gatekeeper' in colorectal tumorigenesis . In FAP patients, mutation or loss of the wildtype allele of APC may thus be a rate-limiting step in tumor initiation. Somatic mutations of APC are also thought to play a key role in early stages of tumorigenesis in a subset of HNPCC patients (Huang et al., 1996; Konishi et al., 1996) and in most sporadic cases of colorectal cancer .
APC encodes a 2843 amino acid cytoplasmic protein, one of whose normal functions is to facilitate the ubiquitination and destruction of b-catenin, a protein involved in both cell adhesion and signal transduction (Polakis, 1997; Willert and Nusse, 1998) . This activity of APC is localized to the central region of the protein, which contains a series of seven 20-amino acid (aa) b-catenin binding repeats (Rubinfeld et al., 1997) , and three Ser-Ala-Met-Pro (SAMP) repeats which are sites of interaction with the proteins Conductin or Axin (Behrens et al., 1998; Hart et al., 1998) . Nearly all of the tumor-associated somatic mutations in human APC occur within the ®rst 1500 codons and approximately two-thirds are con®ned to a mutation cluster region (MCR) between codons 1286 and 1513 (Miyaki et al., 1994; Miyoshi et al., 1992) . These tumor-associated mutations give rise to truncated APC proteins that have lost ®ve or six of the 20-aa repeats and are unable to down-regulate bcatenin (Polakis, 1997; Rubinfeld et al., 1997) . This results in elevated cytosolic levels of b-catenin and entry of this protein into the nucleus, where it mediates transcriptional regulation in complex with Tcf-4 and other transcription factors Morin et al., 1997; Nusse, 1997) . Among the target genes up-regulated in APC mutant tumor cells are the proto-oncogenes c-Myc and cyclin D1, and the metalloproteinase matrilysin (Crawford et al., 1999; He et al., 1998; Shtutman et al., 1999; Tetsu and McCormick, 1999) .
The availability of mice carrying targeted gene disruptions in Mlh1 and Apc provides an opportunity to examine the mechanisms by which these mutations cause cancer predisposition. Mlh1 mutant mice are predisposed to developing a spectrum of cancers, including tumors of the gastrointestinal tract (Edelmann et al., 1996 . However, unlike HNPCC patients with MLH1 germline mutations, the predisposition of these mice to gastrointestinal tumors shows low penetrance and is observed in only 14 and 33% of heterozygous and homozygous Mlh1 animals, respectively . The mice frequently develop lymphoma, which may cause death before the eects of Mlh1 de®ciency on the gastrointestinal tract become apparent. To create a model system to study the eects of Mlh1 de®ciency in intestinal tumorigenesis, we previously crossed Mlh1 7/7 mice with the Apc 1638N strain which carries a heterozygous germline mutation in Apc. Apc 1638N mice typically develop three to ®ve intestinal tumors per animal within 9 months, and 475% of these display allelic loss of the wild-type Apc allele (Yang et al., 1997; Smits et al., 1997) . Compared to other Apc mutant strains, such as Apc Min and Apc D716 (Moser et al., 1990; Su et al., 1992; Oshima et al., 1995) , Apc 1638N displays a relatively mild phenotype and is longer lived. This makes it an ideal model in which to study additional risk factors in intestinal tumorigenesis, such as MMR de®ciency. The multiplicity of intestinal tumors was increased dramatically in the Mlh1
7/7
Apc 1638N double mutant strain, with an average of 440 tumors per mouse by 3 months of age . This increase was associated with somatic mutations in the wildtype Apc allele.
In the present study, we have examined in detail the nature and distribution of 91 tumor-associated Apc mutations in Mlh1 Apc 1638N mice promotes truncation mutations in Apc, we analysed Apc sequences from intestinal tumor DNA samples by in vitro transcription and translation (IVTT). Apc sequences were ampli®ed by PCR with primers speci®c for the wildtype allele and IVTT products were analysed by SDS-polyacrylamide gel electrophoresis. In view of prior mutational analysis of Apc in humans and mice, the regions of Apc considered most likely to contain mutations were those designated Segment 2 and Segment 3 in Figure 1 Shoemaker et al., 1997) . Segment 2 is the predominant site of ENU-induced Apc mutations reported in Apc Min mice (Shoemaker et al., 1997) , while Segment 3 is equivalent to the mutation cluster region (MCR) described in human colorectal cancers (Miyoshi et al., 1992) .
A total of 44 tumor DNA samples from Mlh1
Apc 1638N mice were analysed in this way, and truncated Apc products were detected in 37 of them ( -derived tumors. Collectively, these results indicate that the predominant mechanism of Apc inactivation in tumors is altered from allelic loss to intragenic mutation as a result of Mlh1 de®ciency.
Allele-specificity of Apc mutations
A large proportion of the tumor samples analysed (66%) showed more than one novel-sized truncated polypeptide by IVTT. To test the possibility that secondary mutations had occurred in the Apc   1638N allele in addition to mutations in the wildtype allele, we analysed selected tumor samples using PCR primers speci®c for each of the two alleles. As illustrated in Figure 2 , we found that the truncated products were derived exclusively from formerly wildtype alleles. We also explored the possibility that an individual Apc allele might have suered multiple mutations. To do this, we analysed 12 tumor samples in which the two detected mutations mapped within the fragment ampli®ed for segment 2 analysis. Sequencing of clones bearing the upstream mutation showed that they were wildtype for the downstream mutation (data not shown). This suggested that when multiple mutations were identi®ed in a given tumor sample, they were located on separate Apc alleles. We concluded that in those cases the mutations were derived either from polyclonal tumors, or from two or more adjacent tumors that were not separated during dissection.
Apc mutations in Mlh1
To characterize the Mlh1
-derived mutations in Apc at the molecular level, we cloned the relevant PCR reaction products, identi®ed mutant clones by IVTT analysis, and characterized a total of 91 Mlh1
7/7
Apc 1638N -derived mutations by sequencing. The mutant sequences are summarized in Table 2A and their locations within Apc are shown in Figure 3 . Each of the 91 mutations is predicted to cause either premature termination or a frameshift in the Apc polypeptide between codons 791 and 1464 ( Figure 3 ). Approximately half of the mutations were located upstream of codon 1019, resulting in loss of all the known b-catenin binding domains, and all were located upstream of the ®rst SAMP repeat (codon 1562 ± 1593).
The Apc truncation mutations detected in Mlh1
tumors were a mixture of base substitutions and frameshift mutations (27 and 73%, respectively; Table 3 ). The base substitutions were predominantly C?T transitions, and 21 of 25 occurred at CpG dinucleotides within an Arginine codon (Table  2A) . A particular hotspot for base substitutions was at codon 854, which is preceded by a short tract of AG dinucleotide repeats (Table 2A, Figure 3 ). We found 16
Figure 1 APC protein. Known structural motifs and segments analysed for chain termination mutations are indicated. The APC mutation cluster region (Human MCR: codons 1286 ± 1513), de®ned in human colorectal cancers (Miyaki et al., 1994; Miyoshi et al., 1992) , and the region of APC found to contain truncation mutations in tumors of ENU-treated Apc Min mice (ENU-MCR; codons 971 ± 1197) (Shoemaker et al., 1997) , are shown above the line diagram. Structural domains shown in the diagram are as follows: the N-terminal oligomerization domain (oligo); seven repeats of 42 amino acids (arm repeats) ®rst described in the Drosophila Armadillo protein Kinzler et al., 1991; Peifer et al., 1994) ; three 15-aa repeats (A,B,C) which represent constitutive binding sites for b-catenin (Rubinfeld et al., 1993; Su et al., 1993) ; seven 20-aa repeats (1 ± 7) which are kinaseregulated b-catenin binding sites (Munemitsu et al., 1995; Rubinfeld et al., 1993) ; three SAMP repeats (S1, S2, S3) which are binding sites for Conductin or Axin, proteins also involved in down-regulation of b-catenin (Behrens et al., 1998; Hart et al., 1998) ; a basic domain (basic) which may mediate interactions with microtubules (Munemitsu et al., 1994; Smith et al., 1994) ; and a C-terminal binding site for the mammalian homolog of the Drosophila septate junction protein Discs Large (dlg) (Matsumine et al., 1996) . The site at which the Apc 1638N allele is disrupted by insertion of a neo cassette is indicated by an arrow at amino acid 1638 (Fodde et al., 1994) . For analysis of Apc mutations in tumors from Mlh1
Apc 1638N mice, codons 664 ± 1714 of exon 15 were ®rst ampli®ed with wildtype allele-speci®c primers and then reampli®ed with primers speci®c for Segment 2 (codons 677 ± 1234) or Segment 3 (codons 1097 ± 1690). These products were then analysed by in vitro transcription and translation (IVTT) Apc 1638N mice. Apc polypeptides derived from allele-speci®c PCR and IVTT were analysed by SDS ± PAGE. Only analysis of Segment 2 is shown. Lane 1, molecular weight markers. Lane 11, control (C): full length Apc segment 2 polypeptide derived from control genomic DNA. The segment 2 product has an apparent MW of approximately a 75 kD (open arrowhead). Lanes 2 ± 10, analysis of tumor samples T16, T18, and T19. PCR primers were speci®c for both alleles (B; lanes 2, 5, and 8), the wildtype allele (W; lanes 3, 6 and 9) or for the Apc 1638N mutant allele (M; lanes 4, 7 and 10). For each tumor sample analysed, novel sized bands were detected only in the products of reactions that ampli®ed the wildtype Apc allele (lanes 2, 3, 5, 6, 8, and 9; ®lled arrowheads) independent examples of C?T transition at this site, each converting the Arg codon to a Stop codon.
The numerous frameshift mutations occurred exclusively within runs of mono-or di-nucleotide repeats (Table 2A) . The majority were associated with dinucleotide repeats (Table 3) , and there were particularly striking hotspots at codons 927 ± 929, 1209 ± 1211 and 1461 ± 1464 (Figure 3) animals. Since fewer than 30% of these tumors showed truncation mutations in Apc, we only characterized a total of ®ve such mutations. Sequencing showed that none of these was the same as observed in Mlh1-de®cient tumors (Table 2B ). Instead of frameshift mutations occurring within runs of nucleotide repeats, the one frameshift found was an 8 bp deletion combined with a single base insertion and was not associated with repetitive sequences. The other four mutations were base substitutions. However, unlike the Mlh1
Apc 1638N -derived mutations, there was no apparent preponderance of C?T transitions within Arginine codons. Although based on a small sample size, these data appear consistent with the idea that the nature of the mutations resulting in Apc truncation in tumors is altered by loss of Mlh1 function.
Finally, to investigate whether the above spectrum of Apc mutations in Mlh1
Apc 1638N mice is related to Mlh1 de®ciency independently of Apc genotype, we also characterized the Apc status in four of the rare intestinal tumors of Mlh1
Apc +/+ mice. Three out of four tumor samples showed Apc truncation by IVTT and one had two separate mutations. All four of the mutations detected were due to dinucleotide deletions (Table 2A) . Importantly, three of the four were at the hotspots for dinucleotide deletion found in Mlh1 7/7 Apc 1638N -derived tumors. These data strongly suggest that the observed hotspots are Mlh1-de®ciency speci®c and that the spectrum of Apc mutations that we have described is not signi®cantly aected by the presence or absence of an Apc germline mutation. Apc   1638N mouse model have shown that the most common mechanism of Apc inactivation in the tumors of these animals is through allelic loss (Smits et al., 1997 and the higher incidence of tumor initiation is therefore attributable to the increased frequency of truncation mutations in Apc. A recent study of tumorigenesis in Mlh1-de®cient Apc Min mice also detected Apc truncations by IVTT in a proportion of the tumors of that strain (Shoemaker et al., 2000) . Our data demonstrate that the prevailing mechanism of Apc inactivation in Apc   1638N mice is changed, from allelic loss to truncation mutation, as a result of Mlh1 de®ciency. They also illustrate a direct eect of the Mlh1 defect in promoting mutations that contribute to tumorigenesis and imply that a major target for such mutations in the gastrointestinal tumors of these mice is the tumor suppressor gene Apc.
Discussion

Previous studies of intestinal tumorigenesis in the
For comparison with the Apc mutations found in Mlh1
7/7
Apc 1638N mice, we also analysed four intestinal tumors from Mlh1 7/7 animals that were wild-type for Apc. The number of samples was restricted due to the low incidence of intestinal tumors in Mlh1 7/7 Apc +/+ mice . However, three out of four tumors contained truncation mutations, a frequency that appears similar to that seen in Mlh1 Apc 1638N strain as a useful model of human HNPCC.
While the majority of the tumor samples we analysed contained truncation mutations in Apc, there were several tumors in which Apc mutations were undetectable by the PCR-IVTT assays. In a signi®cant proportion of these tumors, we expect there to be allelic loss of Apc, as documented in 475% of the spontaneous intestinal tumors of Apc 1638N mice (Smits et al., 1997). It is formally possible that some tumors may contain truncation mutations in Apc outside the region tested, or missense mutations that impair Apc function, but there are very few precedents for these in other systems. Perhaps more likely is that in some cases tumorigenesis is initated by mutations in genes other than Apc. For example, mutational activation of bcatenin has been described in some instances of human colorectal cancer and this may by-pass the need for APC mutations (Kitaeva et al., 1997; Miyaki et al., 1999; Morin et al., 1997) . Miyaki et al. (1999) 7/7 genotype caused a 410-fold increase in tumor incidence, the proportion of tumor-associated mutations in our data set which are due to spontaneous mechanisms is likely to be very low. Of the base substitutions that caused Apc truncation in Mlh1
Apc 1638N tumors, more than 80% were C?T mutations at CpG dinucleotides, the principal target site for DNA methylation. Mutations at such sites can arise by spontaneous deamination of 5-methylcytosine to T, causing a G : T mismatch. An unrepaired mismatch then leads to transition mutations. Analysis of colorectal tumors has shown that C:G?T : A transitions are also the most frequent spontaneous substitution mutations in human APC (Huang et al., 1996) . In Mlh1
Apc 1638N mice, we found that the Arg854 codon (CGA) was a prominent hotspot for tumor-associated C?T transition mutations in Apc, accounting for 64% of all base substitutions detected. The relevant hotspot is a CpG site preceded by four AG dinucleotides and it is perhaps surprising that this is not a preferred site for dinucleotide slippage mutations rather than base substitutions. A CGA Arginine codon in the HPRT locus has also been reported to be a hotspot for transition mutations in a human cancer cell line with an MLH1 mutation (Ohzeki et al., 1997) .
Three hotspots for frameshift mutations in Apc were observed in Mlh1
Apc 1638N intestinal tumors. These were at codons 927 ± 929, 1209 ± 1211 and 1461 ± 1464, where there are tandem dinucleotide repeats of (CA) 4 , (TC) 4 , and (AG) 5 , respectively (Table 2A) . The other sites of deletion/insertion were also at short runs of mono-or di-nucleotide repeats. The features of these deletion/insertion sites can be explained by replication slippage and are consistent with the reported microsatellite instability in Mlh 7/7 mouse cells and human colorectal cancer cell lines (Edelmann et al., 1996; Parsons et al., 1993; Bhattacharyya et al., 1994; Li and Modrich, 1995) . APC mutations at mononucleotide tracts, particularly of adenine, are common in human colorectal tumors that exhibit microsatellite instability (Huang et al., 1996) . However, the most frequent type of mutation of Apc in tumors from Mlh1 7/7 Apc 1638N mice was dinucleotide deletion within a tract of four or more dinucleotide repeats. Such mutations account for the three principal hotspots for frameshift mutations. Two of these hotspot sequences are not present in human APC. In contrast, the (AG) 5 hotspot at codons 1461 ± 1464, and the (A) 4 tracts at codons 866 ± 867 and 973 ± 974, are also present in human APC and frameshift mutations at these sequences have been described in human colorectal tumors (Huang et al., 1996; Miyaki et al., 1994) . It is not yet known whether such mutations are preferentially found in tumors with hMLH1 de®ciency. However, similar short repetitive sequences at the HPRT locus were frequent targets of frameshift mutation in an hMLH1-mutant cell line (Bhattacharyya et al., 1994; Ohzeki et al., 1997) .
The characteristics of the Apc deletion/insertion mutations we observed in Mlh1
Apc 1638N mice suggest that under normal circumstances MMR complexes containing Mlh1 protein eciently recognize dinucleotide slippages and target them for repair. Our analysis is unable to assay for trinucleotide slippage, but indicates that Mlh1-containing complexes can also recognize base substitution mutations and mononucleotide slippages. These observations are consistent with Mlh1-Pms2 forming ternary complexes with either Msh2-Msh6 or Msh2-Msh3 on mismatched DNA, as previously shown in yeast (Habraken et al., 1997 (Habraken et al., , 1998 , since the MSH2-MSH6 complex predominantly recognizes base-base mismatches, while MSH2-MSH3 recognizes small insertion/deletion loops (Kolodner, 1996) . We believe that our results provide the most detailed analysis to date of mutations speci®cally attributable to Mlh1 de®ciency in a mammalian system in vivo. The mutational spectrum we have observed in Mlh1 7/7 Apc 1638N mice demonstrates that Mlh1 de®ciency promotes mutations caused by slippage at short repetitive sequences and certain base mismatches, and con®rms several of the predictions from yeast and human cell lines (Bhattacharyya et al., 1994; Kolodner, 1996; Ohzeki et al., 1997; Parsons et al., 1993; Prolla et al., 1994a) . Apc +/+ tumors were located upstream of the third 20-aa b-catenin binding repeat and the ®rst Axin/Conductin-binding site (SAMP repeat, see Figure 3 ). In human APC, the majority of somatic truncation mutations in tumors are concentrated in the centrally localized MCR between codons 1286 and 1523 (Miyaki et al., 1994; Miyoshi et al., 1992) . These mutations result in a truncated protein typically retaining one or two 20-aa repeats but lacking the remaining C-terminal structural motifs (see Figure  1) . Strikingly, 95% of the somatic APC mutations identi®ed in tumors from FAP patients are con®ned to the MCR, and patients with a germline mutation in the MCR have a generally poorer prognosis than those with mutations elsewhere in the gene (Miyaki et al., 1994) . The prevalence of APC mutation is reported to be somewhat lower in HNPCC colorectal tumors (21 ± 53%; Huang et al., 1996; Konishi et al., 1996) than in FAP or sporadic tumors (470%; Huang et al., 1996; Konishi et al., 1996; Miyaki et al., 1994; Miyoshi et al., 1992; Sparks et al., 1998) but the mutations typically lie within this same region of APC.
Distribution of truncation mutations within
In experimental assays of APC function, binding of APC polypeptides to b-catenin required retention of only a single 20-aa repeat, while at least three of these repeats were required for down-regulation of b-catenin (Rubinfeld et al., 1997) . Similarly, a truncated Apc protein that retains three 20-aa repeats and the ®rst SAMP repeat but lacks the remainder of the Cterminus, was capable of down-regulating b-catenin and this mutant did not cause tumor predisposition in mice (Smits et al., 1999) . Although the presence of SAMP repeats in a truncated APC product appears necessary for optimal regulation of b-catenin levels (Behrens et al., 1998; Hart et al., 1998) , shorter polypeptides containing three 20-aa repeats but none of the SAMP repeats were only slightly impaired in their ability to antagonize b-catenin/Tcf signaling (Rubinfeld et al., 1997; Smits et al., 1999) . In addition, it has recently been reported that 20-aa repeats three and four of APC contain nuclear export signals whose loss may further impair the protein's ability to modulate b-catenin signaling (Rosin-Arbesfeld et al., 2000) . Collectively these data suggest that somatic mutations in the MCR give a selective advantage during tumor initiation because at least ®ve of the seven 20-aa repeats are eliminated and this results in loss of b-catenin regulation by APC. In support of this model, all the somatic mutations we identi®ed in tumors from Mlh1
7/7
Apc +/+ and Mlh1
Apc 1638N mice resulted in truncated polypeptides lacking all the SAMP repeats and at least ®ve of the 20-aa repeats (Figure 3) . It is notable that these mutations were detected exclusively in the formerly wildtype allele and not in the functionally defective Apc 1638N allele. This observation allows us to conclude that the Apc mutations contribute functionally to tumorigenesis and are not simply manifestations of an increased mutation rate in the Mlh1 7/7 tumors.
Materials and methods
Experimental mice and tissue samples
The animals analysed in this study were generated by crossing Apc 1638N mice and 10 tumors from Apc 1638N mice were collected. In each case, the entire intestinal tract was removed, opened along its length and rinsed brie¯y in PBS. All intestinal tumors visible to the naked eye were then dissected from the intestinal epithelium. Tissue samples were immediately frozen in liquid nitrogen. Genomic DNA was prepared from freshly frozen tissue samples by Proteinase K digestion followed by puri®cation using a QIAamp Tissue kit (Qiagen).
Analysis of Apc truncation mutations
Codons 677 ± 1690 of the mouse Apc gene were analysed for truncation mutations by PCR and in vitro transcription and translation (IVTT) as described previously . To eliminate co-ampli®cation of the inactivated Apc 1638N allele, PCR ampli®cation was performed in two stages using the forward primer 5'-TACAGCACTTGAAATCTCACAG-3' (nucleotides 1991 ± 2012 of mouse Apc; Genbank accession no. M88127) and a wildtype allele-speci®c reverse primer 5'-GTTGTCATCCAGGTCTGGTG-3' (nucleotides 5123 ± 5142). 150 ± 200 ng of genomic DNA from frozen tumor and non-tumor tissue samples was ampli®ed in 20 ml reactions containing 10 mM Tris-HCl, pH 8.6, 50 mM KCl, 0.1% Triton X-100, 1 mM MgCl 2 , 0.2 mM dNTP, 0.2 mM primers, and 1 unit of Taq2000 (Stratagene). Cycling conditions were one cycle of 948C for 5 min, followed by 25 cycles of 948C for 30 s, 608C for 1.5 min, and 728C for 2 min, with ®nal extension at 728C for 5 min. This gave products of approximately 3.2 kb. Two overlapping segments of the Apc gene (segments 2 and 3, see Figure 1 ) covering codons 677 ± 1234 and 1097 ± 1690 were then ampli®ed from aliquots of the ®rst reactions using two pairs of speci®c PCR primers for IVTT. The primers were based on those described by Levy et al. (1994) but were modi®ed to contain suitable restriction sites as follows. Segment 2, forward primer: 5'-CGGGATCCTAATACGACT-CACTAT AGGGAGACCACC ATGGATGC ATGTGGAA-CTTTGTGG-3'; reverse primer: 5'-CGATCGAAGCT-TGGACGCAGCTGATTCT-3'. Segment 3, forward primer: 5'-GCGGAT CCTAATACGA CTCACTATA GGGAGACC-ACCATGGTTTCCCCATATAGGTCAAGG-3'; reverse primer: 5'-CGATCGAAGCTTCTGTAGGAATGGTATCTCG-3'. PCR was performed in 50 ml reactions containing 2 ml aliquots of the ®rst-stage reactions, 0.3 mM primers, 10 mM Tris-HCl, 50 mM KCl, 0.1% Triton X-100, 0.2 mM dNTP, and 2.5 units of Taq2000 (Stratagene). For ampli®cation of segment 2, the pH of the buer was 8.6 and the reaction contained 1 mM MgCl 2 ; for segment 3 the buer was at pH 8.3 and contained 1.5 mM MgCl 2 . Cycling conditions for both segments were as above but for 20 cycles with an annealing temperature of 578C. After puri®cation by QIAquick PCR puri®cation kit (Qiagen), 50 ± 100 ng of puri®ed PCR products were used as templates in 6 ml IVTT reactions (TNT T7 Quick Coupled Transcription/Translation System, Promega) containing 2.5 mCi of [ 35 S]methionine (Amersham). The reactions were incubated at 308C for 1 h. Aliquots of the IVTT reactions were diluted 10-fold in SDS sample buer, denatured at 1008C for 5 min, and then analysed by 12% SDS ± PAGE and¯uoro-graphy. For characterization of tumor-speci®c mutations, the PCR products were double-digested with BamHI and HindIII, gel-puri®ed and ligated into an SP64 plasmid vector. Individual clones were screened by IVTT to identify those carrying mutations and their DNA sequence was then determined by the Rockefeller University DNA Sequencing Facility.
Allele-specific PCR
To con®rm that the detected Apc mutations occurred in the wildtype allele, 11 tumor samples were analysed by amplifying both alleles separately prior to ampli®cation of Apc segments 2 and 3. The ®rst stage reaction for ampli®cation of wildtype Apc allele sequences was as described above. For ampli®cation of Apc 1638N allele sequences, an Apc   1638N -speci®c reverse primer, 5'-TGGAAG-GATTGGAGCTACGG-3' was substituted for the wildtype allele-speci®c reverse primer. Products of approximately 3.2 kb were obtained from each allele. Two ml aliquots of the ®rst-stage reactions were reampli®ed in 50 ml reactions containing 0.3 mM each of either the Apc segment two or three primers described above. Apc 1638N allele-speci®c Apc segment 3 was ampli®ed by the combination of segment 3 forward primer with the Apc 1638N -speci®c reverse primer. Final PCR products were then purifed and used as templates in IVTT assays. postdoctoral fellowship from the Cancer Research Foundation of America (to M Karaguchi); an Irma T Hirschl Career Scientist Award (to A Brown); and by funding from NIH grants CA76329 (to W Edelmann), CA67944 and N01-CN-65031 (to M Lipkin and R Karaguchi), CA13330 to Albert Einstein College of Medicine, and CA29502 and CA47207 (to A Brown).
